Intrinsiqq
BioVie Inc. logo

BioVie Inc. Financials

BIVI

Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 5 of 14 available years
Income Statement
JUN 2026
5:1 split
JUN 2025
~3.3:1 split
JUN 2024
~1.4:1 split
JUN 2023
~1.3:1 split
JUN 2022
2:1 split
General & Administrative$9$9$9$12$10
Research & Development$14$9$23$33$17
Total Operating Expenses$23$18$32$45$27
Operating Income-$23-$18-$32-$45-$27
Non-Operating
Net Interest Expense-$0-$0-$3-$4-$2
Other Non-Operating Income (Expense)$1$1$0-$5–
Net Income
Net Income-$22-$18-$32-$50-$26
EPS (Basic)-$3.05-$12.12-$73.05-$154.70-$106.00
EPS (Diluted)-$3.05-$12.12-$73.05-$154.70-$106.00
Weighted Avg Shares (Basic)7.2M1.5M4.5M32.5M24.7M
Weighted Avg Shares (Diluted)7.2M1.5M4.5M32.5M24.7M
Shares Outstanding7.2M1.5M451,853.3324,834.89246,625.57

BioVie (BIVI) financials: revenue, profit and margins

BioVie (BIVI) generated about n/a in revenue and -$23 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is BioVie profitable?+

BioVie reported about -$23 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 5 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 9 Nov 2026. How this is calculated.

Fiscal year ends Jun.

Peers

Pharmaceutical Preparations · Pick stocks to compare with BIVI

CompareIntrinsic value
ROIVRoivant Sciences Ltd
$38.66-0.78%42
FHTXFoghorn Therapeutics Inc.
$1.72-3.37%46
OCULOcular Therapeutix Inc.
$5.57-4.95%10
TNGXTango Therapeutics Inc.
$21.73-4.32%25
PVLAPavella Therapeutics Inc.
$143.21-1.76%40
XERSXeris Biopharma Holdings, Inc.
$16.97+2.11%34
ACADAcadia Pharmaceuticals Inc.
$17.38-1.19%71
PTGXProtagonist Therapeutics Inc.
$121.40-2.11%62

Spot a number that looks wrong? Check it in BIVI's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing BIVI

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.